AstraZeneca Crashes the Obesity Party, Takeda Topples Sotyktu, and a Record Biotech IPO – This Week in Biotech #104
Elecoglipron makes obesity a four-player race, zasocitinib beats Bristol Myers Squibb head-to-head, and Parabilis prices the biggest venture-backed biotech IPO ever (6/5–6/11).
Welcome back to This Week in Biotech by Biotech Blueprint, edition 104, covering biotech and pharma news from June 5 to June 11, 2026.
🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.
🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.
👥 If you haven’t already, please connect with me or follow me on LinkedIn.
VIDEO SUMMARY
THIS WEEK’S KEY TAKEAWAYS 🔑
This week belonged to metabolism. The American Diabetes Association meeting in New Orleans pushed the obesity conversation into a new phase. For three years the story has been Lilly versus Novo and this week it became a four player field. AstraZeneca put real Phase 2 numbers behind its oral GLP-1 pill elecoglipron, 10.5% weight loss at 26 weeks rising to 11.8% at 36 with no plateau, and committed to a sprawling Phase 3 program anchoring what it now frames as a $5 billion cardiometabolic franchise. AstraZeneca is now the third large cap with a credible oral incretin in pivotal development, behind Lilly’s Foundayo and alongside Pfizer’s Metsera assets. The efficacy isn’t class leading, but you don’t need to be best in class to compete in this market anymore. You just need to be good enough, which says a lot about how big the opportunity has become.
The most important obesity development this week wasn’t about a drug. More US employers are planning to drop GLP-1 coverage for weight loss in 2027 because too many of their employees are taking the drugs. Real world persistence is the problem nobody likes to talk about: adherence falls from 65% at 120 days to 34% at one year. The efficacy race, retatrutide at 28.3% in 80 weeks, CagriSema at 23% in 84, is happening on top of a reimbursement system that’s starting to give way. The next phase of this market isn’t about who loses the most weight, but who can stay on the drug long enough, and affordably enough, for the weight loss to matter.
Outside of obesity, the week had its share of platform wins and program failures. Novartis got an early payoff from its $12 billion Avidity acquisition with a clean biomarker win for an antisense oligonucleotide conjugate in muscular dystrophy, then doubled down on molecular glues with a second Orionis deal. Takeda’s zasocitinib beat BMS’s marketed Sotyktu head-to-head in psoriasis, the first time one TYK2 inhibitor has shown statistical superiority over another. Meanwhile Sanofi halted a Phase 3 in a rare neuropathy for insufficient efficacy, and Gilead and Merck’s Trodelvy plus Keytruda combination missed in lung cancer even as their once weekly HIV pill succeeded.
Parabilis priced the largest venture-backed biotech IPO in history at $670 million, beating Kailera’s $625 million record from two months ago. The same week, Summit Therapeutics pulled a $500 million share sale a day after announcing it, even though its PD-1/VEGF bispecific ivonescimab headlined the ASCO plenary just two weeks ago. It seems that new stories with strong science are getting funded, but existing companies that haven’t delivered on past wins aren’t.
BIOTECH/PHARMA NEWS 🧬
🔹 AstraZeneca used the American Diabetes Association meeting to convert a licensed asset into a franchise commitment. In the Phase 2 VISTA obesity trial, elecoglipron at 75 mg produced 10.5% mean weight loss at 26 weeks versus 0.6% on placebo, with the curve still climbing to 11.8% at 36 weeks. In the SOLSTICE Type 2 diabetes trial, the same dose cut HbA1c by 1.9% from baseline versus 0.2% on placebo, with 90% of treated patients reaching HbA1c below 7%. No liver safety signals, infrequent discontinuations. The efficacy is roughly in line with, not ahead of, Lilly’s oral orforglipron, which is why some analysts called the pill “relatively underwhelming.” That reading misses the strategy. AstraZeneca is launching the EMBOLD trials in obesity and the ELUMINATE trials in diabetes, including cardiovascular and kidney outcomes studies and a combination with dapagliflozin. A small molecule oral GLP-1 that’s merely competitive on weight but pairs naturally with AstraZeneca’s existing cardio-renal portfolio is a different commercial proposition than a standalone weight loss drug. The obesity market now has four serious players: Lilly, Novo, Pfizer-Metsera, and AstraZeneca. And the fight is no longer about who can produce the biggest weight loss number. It’s about who can win on convenience, combination opportunities, and payer access.
🔹 A growing share of US employers are planning to drop GLP-1 coverage for weight loss in 2027, because too many employees are taking the drugs and the costs have become unsustainable. Real world persistence makes this worse: adherence falls from 65% at 120 days to 34% at one year. The efficacy race between Lilly’s retatrutide and Novo’s CagriSema is happening on top of a reimbursement system that’s starting to give way. The next phase of the market isn’t going to be about who loses the most weight. It’s about who can be taken long enough, and affordably enough, for the weight loss to actually matter.
🔹 Novartis booked two wins on its platform acquisition strategy in one week. First, the biomarker cohort of the FORTITUDE Phase 1/2 trial of del-brax in facioscapulohumeral muscular dystrophy met its primary and key secondary endpoints, with reductions in disease biomarkers indicating strong target engagement and reduced muscle damage. Del-brax is the asset that came through Novartis’s $12B Avidity acquisition that closed in February, and the result validates that price tag while a 200-patient Phase 3 enrolls across the US and Europe. The drug is an antisense oligonucleotide conjugate, extending the modality’s category-defining run into neuromuscular disease after recent wins in hereditary angioedema and metabolic disease. Second, Novartis extended its molecular glue partnership with Orionis Biosciences, paying $40M upfront and up to $1.4B in milestones to apply Orionis’s discovery platform to hard targets. Molecular glues are the cheaper, orally deliverable cousin of the degrader modality that crossed its regulatory threshold this spring with the Veppanu approval. Novartis is buying optionality across both validated and emerging modalities rather than building each in house.
🔹 Gilead and Merck delivered a win and miss this week. The win: the Phase 3 ISLEND-1 and ISLEND-2 trials of a once weekly oral islatravir + lenacapavir regimen met their primary efficacy endpoint with safety comparable to daily standard of care in virologically suppressed patients. This would be the first oral once weekly HIV treatment, a meaningful convenience step that protects Gilead’s core antiviral business against the long acting injectable threat. The miss: the EVOKE-03 trial of Trodelvy + Keytruda versus Keytruda alone in first line PD-L1-high non small cell lung cancer was stopped early, posting a numerical but not statistically significant progression free survival improvement. The miss carries read through beyond Gilead. It lands one week after Merck’s own TROP2 antibody drug conjugate sac-TMT hit in first line lung cancer in a China-only trial, raising the question of whether the TROP2-ADC + checkpoint combination actually works in lung cancer, or whether last week’s win reflects something specific about the comparator and the patient population.
🔹 Parabilis Medicines priced the largest venture-backed biotech IPO on record, selling 33.5M shares at $20 for $670M, beating Kailera’s $625M record set in April. The company, formerly FogPharma and founded by Gregory Verdine, develops helix-shaped peptide drugs called Helicons designed to hit previously undruggable proteins. About $150M will fund the lead asset zolucatetide, a beta-catenin inhibitor heading to Phase 3 in desmoid tumors in the first half of 2027. The IPO extends a 2026 streak of 12 biotech debuts raising more than $4.1B. The same day Parabilis priced, Summit Therapeutics pulled a $500M share sale it had announced just one day earlier, citing market conditions, even though its PD-1/VEGF bispecific ivonescimab headlined the ASCO plenary just two weeks ago. Investors will pay top dollar for fresh precommercial stories and balk at adding to positions that haven’t rewarded prior good news.
🔹 Sanofi halted its Phase 3 MOBILIZE trial of riliprubart in chronic inflammatory demyelinating polyneuropathy after an independent monitoring committee found the study unlikely to show sufficient efficacy. The trial enrolled patients refractory to standard of care. No safety signals were identified. The companion VITALIZE Phase 3 in patients treated with intravenous immunoglobulin will be evaluated separately, but the failure removes one path for a complement-targeting therapy Sanofi had viewed as a potential blockbuster. CIDP is the same indication argenx and others are pursuing, and the futility readout reinforces that mechanistic rationale in autoimmune neurology isn’t translating cleanly into efficacy in refractory patients.
🔹 Takeda’s oral TYK2 inhibitor zasocitinib beat Bristol Myers Squibb’s marketed Sotyktu head-to-head in plaque psoriasis, achieving statistical superiority on all primary and secondary endpoints. At 16 weeks, more than a third of zasocitinib patients achieved complete skin clearance, more than double the rate seen on Sotyktu. This is the second approved therapy zasocitinib has topped, following an earlier win against Amgen’s Otezla. Takeda paid roughly $4B for the asset through its Nimbus Therapeutics deal, and a head-to-head superiority claim against the only marketed oral TYK2 inhibitor is the strongest possible commercial setup. Takeda is targeting a 2026 FDA filing with launch expected in 2027. Sotyktu’s positioning as the premium oral psoriasis option is now directly threatened by a next-generation molecule with cleaner data, before zasocitinib has even reached the market.
🔹 Lilly presented the full TRIUMPH-1 dataset behind its May topline at the ADA meeting. At 80 weeks, retatrutide produced mean weight loss of 28.3% (about 70 pounds) at 12 mg and 25.9% (about 64 pounds) at 9 mg in obesity without diabetes. The triple agonist hitting glucagon, GLP-1, and GIP receptors also showed superior HbA1c and weight reductions versus placebo in the TRANSCEND-T2D-1 diabetes study, with added improvements in systolic blood pressure and lipids. The 28% efficacy ceiling retatrutide set is now reinforced with full peer-presented data, and it reframes every competitor. Novo’s CagriSema, at 23% over 84 weeks, sits a tier below, and Novo’s chief scientific officer publicly conceded the jury is still out on how CagriSema stacks up against the tri-agonist. The retatrutide program now spans diabetes, obesity, sleep apnea, MASH, and cardiometabolic outcomes, making it less a drug and more a metabolic platform.
BIOTECH/PHARMA NEWS 🧬
Have a great rest of your week and thanks for reading Biotech Blueprint!
DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.
DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.
LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.
Image source: Angus Liu/Fierce Pharma
Muy interesante post, aporta mucho valor.